Best Peptides for Fat Loss: Ranked by Evidence

Best Peptides for Fat Loss, Ranked by Evidence

Search this topic and you will find the same article rewritten fifty times: ten peptides, ten glowing paragraphs, zero distinctions between a molecule with regulatory approval and one that has never been inside a human being. That format sells vials. It does not help you decide anything.

This page ranks fat-loss peptides the way a prescribing clinic ranks them, by the strength of the human evidence. That ordering produces four tiers. Tier 1 is the GLP-1 class, the only peptide category with large randomized human weight-loss trials. Tier 2 is tesamorelin, which holds an actual FDA approval for one specific fat compartment in one specific population. Tier 3 is the growth hormone secretagogues, which earn their place through body composition rather than fat loss directly. Tier 4 is MOTS-c, where the mechanism is exciting and the human data has not caught up. Below all four sits a category most articles skip: peptides sold as fat burners that no honest ranking can include.

One framing note. Evidence tiers are not the same as "what should I take." A narrower-evidence peptide can still be the right tool for a narrower job, which is why how we approach weight-loss peptides Read nextHow We Approach Weight-Loss PeptidesWeight-loss peptides do a narrower, more specific job than a GLP-1: instead of suppressing appetite, they protect lean mass, target visceral fat, and improve how your cells burn fuel. Here is how a provider decides which one fits, and where peptides genuinely help versus where they are oversold.Read article covers matching mechanism to goal. This page answers the prior question: what does the science support, and how strongly.

GLP-1s: The Strongest Class

If the question is "which peptide has the most human evidence for losing fat," the answer is not close. GLP-1 receptor agonists are the best-studied peptide drugs in history. Semaglutide mimics glucagon-like peptide-1, an incretin hormone the small intestine releases after eating: it slows stomach emptying, prompts insulin release in proportion to blood sugar, and signals the brain that you have had enough. The natural hormone survives minutes; semaglutide is engineered to last about a week. Tirzepatide activates a second incretin receptor, GIP, alongside GLP-1.

Drucker DJ, "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1," Cell Metabolism, 2018. (Review of GLP-1 biology and the receptor-agonist drug class.) View study

Now the part most peptide sites bury. The landmark weight-loss trials studied the FDA-approved branded medications: Ozempic and Wegovy for semaglutide, Mounjaro and Zepbound for tirzepatide. PeRx does not prescribe those brands. PeRx providers prescribe compounded semaglutide and tirzepatide, prepared with vitamin B12 by US-based 503A compounding pharmacies. Compounded medications are not FDA-approved, and they were not the products in those trials. The mechanism is the same drug class, which is why providers reach for them, but an honest ranking has to keep the two categories separate rather than borrowing the brands’ trial results.

So the case for a compounded GLP-1 is best made in regulatory and logistical terms, not superlatives. A licensed provider reviews your health assessment before anything is prescribed. If approved, semaglutide runs $249 for a 28-day vial and tirzepatide runs $399, shipped cold-chain and ready to use, on a subscription that renews every 28 days with advance notice and can be cancelled any time. What patients notice, when the medication is working, is practical appetite change: full sooner, less food noise, smaller portions without white-knuckling. Results vary, and the medication is a tool for holding a calorie deficit, not a substitute for one.

One more honest boundary: a GLP-1 suppresses appetite, it does not decide what kind of tissue you lose. Part of rapid scale loss is lean mass, which is exactly why the lower tiers of this list exist and why many providers think about peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article as a pairing question rather than an either-or.

Tesamorelin: The Visceral-Fat Specialist

Tesamorelin is the only peptide on this page that can point to an FDA-approved label about fat. As Egrifta, it is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition where fat accumulates deep in the abdomen around the organs. That is a real regulatory milestone no other peptide here has, and it is also a narrow one: approval in a specific population, for a specific fat compartment. Prescribing it to anyone else is off-label, which is legal and common, but worth saying plainly.

The evidence behind that label is solid by peptide standards. In a randomized trial published in the New England Journal of Medicine, 26 weeks of tesamorelin reduced visceral adipose tissue by roughly 15 percent versus placebo, while largely sparing the subcutaneous fat under the skin. A later JAMA trial extended the finding to liver fat in a similar population. The molecule itself is a growth hormone-releasing hormone analog: it prompts your pituitary to release more of your own GH, and visceral fat happens to be the tissue most responsive to that signal.

Falutz J et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, 2007. (Randomized trial behind the Egrifta approval; ~15% visceral fat reduction at 26 weeks.) View study

Stanley TL et al., "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial," JAMA, 2014. View study

Why rank it below the GLP-1 class despite the approval? Scope. Those trials measured visceral fat in HIV-associated lipodystrophy, not total weight loss in the general population, and applying them to a stubborn belly in an otherwise healthy 45-year-old is an extrapolation, not a proven claim. Where tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide shines is the job the GLP-1s do not do: the deep abdominal fat that drives metabolic trouble, spared lean mass included, which also makes it a frequent companion to or follow-up after a GLP-1. It is a daily injection at $229/month; the dosing rhythm, IGF-1 screening, and trial details live in the tesamorelin guide Read nextTesamorelin 2026: FDA-Approved GHRH for Visceral FatMost peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.Read article .

GH Secretagogues and Body Composition

Tier 3 is where the honest framing has to shift from "fat loss" to "body composition," because the evidence does too. Growth hormone secretagogues like CJC-1295/Ipamorelin Explore PeRxCJC-1295/IpamorelinPulsatile Growth Hormone ReleaseView peptide and sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide do not act on fat cells or appetite directly. They stimulate your pituitary to release more of your own growth hormone, mostly overnight, restoring a pulse that declines steadily with age. GH signaling favors lipolysis and lean-mass maintenance, which is the entire fat-adjacent rationale.

Teichman SL et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults," Journal of Clinical Endocrinology and Metabolism, 2006. (Human study showing sustained GH and IGF-1 elevation; not a weight-loss trial.) View study

Read that citation carefully, because it is representative of the whole tier. Human studies show these peptides reliably raise GH and IGF-1. No trial shows they cause weight loss as an outcome. Anyone ranking CJC-1295/Ipamorelin as a top fat-loss peptide is quietly substituting mechanism for evidence.

So why do they make the list? Because body composition is usually what people actually want when they say fat loss. Lose a lot of scale weight with a third of it muscle and both the mirror and your metabolism got a worse deal than the number suggests. GH-axis support is how providers approach that problem, most often for people in a calorie deficit, on a GLP-1 and struggling to hold protein intake, or training hard past 40. CJC-1295/Ipamorelin is a nightly injection at $299/month; sermorelin is the older, shorter-acting option at $229/month. These are two-to-three-month tools, not two-week ones.

MOTS-c: The Exercise Mimetic

MOTS-c is the most scientifically interesting peptide on this page and the one where the gap between mechanism and human evidence is widest. It is a 16-amino-acid peptide encoded inside mitochondrial DNA, which was itself a surprise when it was described in 2015. It activates AMPK, the same cellular energy sensor that exercise activates, which is why researchers keep using the phrase exercise mimetic. In mice, MOTS-c improved insulin sensitivity, increased fat oxidation, and prevented diet-induced obesity. Later work showed levels rise with exercise in humans and that dosing old mice improved their physical performance.

Lee C et al., "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance," Cell Metabolism, 2015. (The discovery paper; mouse and cell data.) View study

Reynolds JC et al., "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis," Nature Communications, 2021. (Exercise-induced MOTS-c in human plasma; treatment outcomes in mice.) View study

The tier-4 verdict in one sentence: nobody has run a human trial showing MOTS-c causes fat loss. What exists is compelling animal data, human observational work, and a mechanism that fits people whose real bottleneck is metabolic efficiency and exercise capacity rather than appetite. That is a legitimate niche, and it is how providers actually use MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide at $229/month, alongside the training it is meant to amplify. If a website tells you MOTS-c melts fat, it is describing mice. The MOTS-c guide Read nextMOTS-c Dosage Chart: Units, Protocols & EffectsMOTS-c is the 16-amino-acid mitochondrial peptide your body releases during exercise. This guide leads with what most readers came for: a real dosage chart with per-injection amounts, insulin syringe unit conversions, weekly totals, and cycle lengths. Then it covers the AMPK mechanism, the metformin comparison, the 2015 USC discovery story, and an honest read of the evidence.Read article covers the evidence without the varnish.

Peptides That Are Not Worth It for Fat Loss

Every peptide above has at least a defensible rationale. The gray market is full of compounds that do not, sold with the word "peptide" doing the work a clinical trial should be doing. A few worth naming, because they show up in the same search results as everything above.

Adipotide (FTPP). The most dramatic fat-loss data in the animal literature, and the clearest cautionary tale. It works by cutting off blood supply to fat tissue, and primate studies flagged kidney toxicity along the way. Human development stalled years ago. Anything you can buy under this name is a research chemical with a serious known safety signal and no human dosing data.

Gray-market "HGH Frag 176-191." The unregulated cousin of AOD-9604, sold by research-chemical sites with no prescription, no pharmacy oversight, and no verification of what is in the vial. Even the properly manufactured pharmaceutical version produced mixed human results; the version from a website with a disclaimer instead of a pharmacist adds purity risk on top.

5-Amino-1MQ. Marketed everywhere alongside peptides as a metabolism-boosting fat burner. Two problems: it is a small molecule, not a peptide, and there are no published human trials. The NNMT-inhibition mechanism is legitimate laboratory science; the capsules sold on that basis are a bet, not a therapy.

"Lipotropic" and MIC injections. Blends of amino acids and B vitamins sold as fat-burning shots in med spas for decades. The evidence has not improved with age. B vitamins correct deficiencies; they do not burn fat in people who are not deficient.

The same honesty applies inside a legitimate catalog. Some peptides we prescribe and like are simply not fat-loss tools: BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide is a repair peptide, GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide is a skin and tissue peptide, and neither belongs in a fat-loss protocol. A useful rule for the whole category: if a compound is sold as a fat burner and the seller cannot point to a single human trial, the evidence tier is zero, and the price does not matter.

How to Choose

The tiers rank evidence. Choosing still means matching the tool to your actual problem, and a licensed provider makes that call at intake. If appetite defeats every attempt, the GLP-1 class is where the evidence points, with the compounded-versus-brand distinction understood going in. If the specific enemy is deep belly fat that has survived years of dieting, tesamorelin has the most on-target data of anything here. If you are already losing weight and worried about what kind of tissue is going, GH-axis support is the body-composition play. If your bottleneck is metabolic efficiency and exercise capacity, MOTS-c is the mechanistic fit, taken with clear eyes about how thin the human data still is.

Combinations are common, a GLP-1 with tesamorelin or CJC-1295/Ipamorelin riding alongside to protect lean mass is a frequent pattern, but that is a prescribing decision, not a shopping-cart one. Every option on this page requires a prescription, and at PeRx the sequence is fixed: you complete the health assessment, a licensed provider reviews it, and your card is only charged if they approve. Everything ships from US-based 503A compounding pharmacies, cold-chain, ready to use with no reconstitution needed. Browse the full lineup with current availability on the weight-loss peptides page, or start with the deeper framework in how we approach weight-loss peptides Read nextHow We Approach Weight-Loss PeptidesWeight-loss peptides do a narrower, more specific job than a GLP-1: instead of suppressing appetite, they protect lean mass, target visceral fat, and improve how your cells burn fuel. Here is how a provider decides which one fits, and where peptides genuinely help versus where they are oversold.Read article .

Best Peptides for Fat Loss: Common Questions